Bayer wins Norway cancer firm Algeta with raised $2.9 bln offer
OSLO Dec 19 (Reuters) - Bayer has raised its offer for Norway's Algeta, its partner for a new prostate cancer treatment, to 362 Norwegian crowns per share, valuing Algeta's equity at 2.1 billion euros ($2.9 billion).
Bayer in late November offered to pay 336 Norwegian crowns per Algeta share. ($1 = 0.7266 euros) (Reporting by Gwladys Fouche, editing by Terje Solsvik)
- Radar showed missing plane may have turned back: Malaysia military
- Malaysian jetliner may have turned back before vanishing |
- Malaysian plane presumed crashed; questions over false IDs |
- Russian forces tighten grip on Crimea despite U.S. warning |